Malaysia Approves Beyfortus (Nirsevimab) to Guard Infants Against RSV In a move welcomed by pediatric health advocates, Beyfortus (Nirsevimab), the preventive monoclonal antibody developed by Sanofi and AstraZeneca, has been approved by Malaysia’s National Pharmaceutical Regulatory Agency (NPRA) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in infants. The approval…